Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with ...

Multiple Sclerosis cases are rising in India, especially among women, with experts stressing early diagnosis, access to ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

There are four main types of multiple sclerosis (MS), with relapsing remitting MS (RRMS) being the most common. However, some people who have RRMS may eventually develop secondary progressive ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...

Early diagnosis and treatment aim to minimise the impact of multiple sclerosis on their daily lives and extend their ...

MS is a spectrum of diseases, //sometimes mimicking tumors (TMS) The Unseen Struggle That Demands Global Solidarity World ...

The initial proceeds to Immunic from the offering were approximately $65 million, before deducting underwriting discounts and commissions and offering expenses. The Company may receive up to an ...

Baxter rhymes off many of his closest friends he lost over the years who had succumbed to the likes of kidney disease, cancer ...